Sugi Predict

Sugi Predict / Targets / ITGA8

ITGA8

Integrin alpha-8 [Cleaved into: Integrin alph · P53708 · ITGA8 on Sugi Atlas →

1,707 patent compounds predicted against ITGA8, 1,012 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL15557799 SCHEMBL15557799 0.59 17/20
SCHEMBL15455924 SCHEMBL15455924 0.92 16/20
SCHEMBL15456687 SCHEMBL15456687 0.92 16/20
SCHEMBL15456154 SCHEMBL15456154 0.89 16/20
SCHEMBL15456621 SCHEMBL15456621 0.89 16/20
SCHEMBL16918571 SCHEMBL16918571 0.88 16/20
SCHEMBL15557533 SCHEMBL15557533 0.87 16/20
SCHEMBL15557946 SCHEMBL15557946 0.87 16/20
SCHEMBL16918565 SCHEMBL16918565 0.77 16/20
SCHEMBL16918585 SCHEMBL16918585 0.75 16/20
SCHEMBL15557116 SCHEMBL15557116 0.74 16/20
SCHEMBL15557504 SCHEMBL15557504 0.72 16/20
SCHEMBL15456377 SCHEMBL15456377 0.86 15/20
SCHEMBL15456705 SCHEMBL15456705 0.86 15/20
SCHEMBL15456454 SCHEMBL15456454 0.75 15/20
SCHEMBL15456641 SCHEMBL15456641 0.75 15/20
SCHEMBL16918437 SCHEMBL16918437 0.74 15/20
SCHEMBL15456397 SCHEMBL15456397 0.73 15/20
SCHEMBL15456617 SCHEMBL15456617 0.73 15/20
SCHEMBL15456712 SCHEMBL15456712 0.71 15/20

Clinical trials — most relevant to ITGA8 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Outcomes of ICSI Cycles With and Without Letrozole PHASE4UNKNOWN
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. PHASE1/PHASE2RECRUITING
Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours: PHASE2ACTIVE_NOT_RECRUITING
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer PHASE1/PHASE2COMPLETED
Imaging Studies and the Development of Multiple Myeloma PHASE2WITHDRAWN
A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors PHASE1/PHASE2WITHDRAWN
A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I PHASE1WITHDRAWN
A Study to Evaluate Adverse Events and How the Drug Moves Through the Body From Subcutaneous (SC) and Intravenous (IV) Doses of ABBV-382 in Healthy Adult Chinese Volunteers PHASE1COMPLETED
Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors PHASE1COMPLETED
68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Stroke EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Myocardial Infarction EARLY_PHASE1UNKNOWN
99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients EARLY_PHASE1COMPLETED
Potential Role of microRNA 410 and BIRC7 Pathways in Recurrent Spontaneous Miscarriage nanCOMPLETED
Angiogenesis and Fibrosis in Myocardial Infarction nanCOMPLETED
The Development of a Clinical Test to Assess the Inflammatory Phenotype of Asthma nanCOMPLETED
The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis nanUNKNOWN
Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis nanCOMPLETED
Effect of Mepolizumab on Severe Eosinophilic Asthma nanUNKNOWN
Angiogenesis and Fibrosis in Aortic Stenosis nanCOMPLETED
The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications nanCOMPLETED
The Role of the Novel 99mTc-NC100692 Tracer in Patients at High Risk or Known Breast Cancer nanUNKNOWN
Ischemic Preconditioning of Liver in Cadaver Donors nanCOMPLETED
Phenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA) nanUNKNOWN
IMaging Pilot Study of the αvβ6 Integrin Radiotracer [18F]-A20FMDV2 in PAtients With Solid Cancer Types nanCOMPLETED
In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer nanCOMPLETED
Biomarkers in the Diagnosis and Prognosis of NAFLD nanRECRUITING
The MyoThrombus Study nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ITGA8 binder may also engage these)

ProteinNameSimilarity
A2ARA8 — 1.000 A2ARA8 →
P26009 — 0.999 P26009 →
Q13797 — 0.994 Q13797 →
B8JK39 — 0.992 B8JK39 →
Q62469 — 0.992 Q62469 →
P61622 — 0.990 P61622 →
ITGA4 Integrin alpha-4 0.990 landscape →
Q00651 — 0.989 Q00651 →
P43406 — 0.989 P43406 →
ITGAV Integrin alpha-V 0.989 landscape →
Q62470 — 0.988 Q62470 →
P26006 — 0.987 P26006 →
Q9UKX5 — 0.987 Q9UKX5 →
P80746 — 0.985 P80746 →
F1MMS9 — 0.985 F1MMS9 →
P26008 — 0.985 P26008 →
Q06274 — 0.984 Q06274 →
Q13683 — 0.983 Q13683 →
P17852 — 0.983 P17852 →
P53710 — 0.983 P53710 →
Q63258 — 0.983 Q63258 →
ITGA2 Integrin alpha-2 0.982 landscape →
P38570 — 0.981 P38570 →
P11688 — 0.980 P11688 →
ITGAL Integrin alpha-L 0.978 landscape →
ITGA5 Integrin alpha-5 0.977 landscape →
Q61738 — 0.976 Q61738 →
ITGAM Integrin alpha-M 0.976 landscape →
Q91687 — 0.975 Q91687 →
P05555 — 0.975 P05555 →